BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

NueCell Bio Joins CIRM Partnership to Accelerate Cell and Gene Therapies from Discovery to GMP Readiness

NueCell Bio, a translational development partner that helps advance cell therapies from scientific discovery to GMP readiness, announced it has joined the ...

October 16, 2026 | News

Nuevocor Doses First Patient in Phase 1/2 Gene Therapy Trial for Inherited Cardiomyopathy

Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening...

October 13, 2026 | News

CellFiber Launches Zeito™ Cell Fibre Fabrication Systems in Japan and US to Advance Cell Therapy Manufacturing

CellFiber, a biotechnology company specialising in cell and gene therapy technologies, has announced the official launch of its Zeito™ series of cell...

October 09, 2026 | News

Every CAR-T Therapy Approved in Asia-Pacific, and What It Costs

Method in brief What counts. A CAR-T cell therapy approved on one of seven national registers: China's NMPA, Japan's PMDA and MHLW, Korea's MFDS, ...

October 08, 2026 | Analysis

iRegene Advances Off-the-Shelf Retinal Cell Therapy Into Clinical Trials in US and China

Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. iReg...

September 30, 2026 | News

Bio-Techne Opens Düsseldorf Flagship Centre to Accelerate Life Sciences Innovation Across Europe

New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and ...

September 24, 2026 | News

OGT Expands SureSeq NGS Indexing Capacity to 384 Samples per Run

OGT, a leading global provider of genomic research and diagnostic solutions, announced the expansion of its SureSeq™ Universal NGS Unique Dual Index ...

September 21, 2026 | News

Australia’s VVMF Secures TGA GMP Licence for Viral Vector Manufacturing

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first viral vector Contract Development and Manufacturing Organisation (CDMO) advises...

September 18, 2026 | News

Alteogen, Novartis Ink Up to $3.2B Deal for Subcutaneous Biologics Using ALT-B4

Novartis obtains rights to develop and commercialize subcutaneous formulations for multiple products utilizing ALT-B4 Alteogen's fourth licensing agreem...

September 04, 2026 | News

Genprex Selects Andelyn Biosciences to Scale Up AAV Gene Therapy for Diabetes

Andelyn Biosciences, a leading contract development and manufacturing organization, announced that Genprex, Inc. has selected Andelyn to support scale-up m...

September 03, 2026 | News

US FDA Grants Fast Track Designation to T-MAXIMUM’s Allogeneic CAR-T Therapy for Recurrent Glioblastoma

T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") announced that its investigational allogeneic CAR-T cell therapy MT027 has been granted Fast Track Designation ...

September 02, 2026 | News

CureGene Doses First Subject in Australia Phase I Trial of Oral Metabolic Drug CG-0416

CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist...

August 24, 2026 | News

AbelZeta Secures US FDA IND Clearance for Bispecific CAR-T Therapy C-CAR039 in Large B-cell Lymphoma

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovati...

August 18, 2026 | News

IASO Bio Acquires Singapore’s MediSix Therapeutics to Strengthen Global Cell Therapy Platform

- IASO Biotechnology announced the completion of its acquisition of MediSix Therapeutics , a Singapore-based immune cell engineering and cell therapy compa...

August 17, 2026 | News

Stay Connected